Skip to main content
S.Biomedics Co., Ltd. logo

S.Biomedics Co., Ltd. — Investor Relations & Filings

Ticker · 304360 ISIN · KR7304360001 KO Professional, scientific and technical activities
Open in API
Filings indexed 138 across all filing types
Latest filing 2026-03-13 Proxy Solicitation & In…
Country KR South Korea
Listing KO 304360

About S.Biomedics Co., Ltd.

https://www.sbiomedics.com/eng/

S.Biomedics Co., Ltd. is a company specializing in the research and development of cell therapies for regenerative medicine. Established in 2005, the company focuses on creating, manufacturing, and supplying stem cell-based therapeutic products. Its core activities involve leveraging data-driven biology to develop fundamental and safe treatments for various conditions, with a significant focus on neurodegenerative disorders such as Parkinson's disease. S.Biomedics is committed to advancing the field of stem cell therapy from initial research to clinical application.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by S-Biomedics. It outlines the date, location, agenda items (such as approval of financial statements, appointment of directors, and amendments to articles of incorporation), and details regarding the meeting. This type of document is a standard proxy solicitation or notice of meeting material provided to shareholders to inform them of upcoming votes, which falls under the Proxy Solicitation & Information Statement category.
2026-03-13 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Audit Report / Information Classification · 95% confidence The document is a regulatory filing from a Korean company (S-Biomedics) disclosing a significant change in financial results (revenue or profit/loss structure change of 30% or more). This is a standard regulatory disclosure requirement in the Korean market (DART system) for listed companies to report preliminary financial performance before the final audit is completed. Since it provides specific financial highlights and reasons for the change rather than just announcing the publication of a report, it fits the 'Earnings Release' (ER) category, which covers initial announcements of financial results. FY 2025
2026-02-27 Korean
[기재정정]전환가액의조정 (제5회차)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from a Korean company (S-Biomedics) regarding the adjustment of the conversion price of convertible bonds (CB). This type of disclosure, which details changes to the capital structure and conversion terms of financial instruments, falls under the 'Capital/Financing Update' category. It is not a report publication announcement, but rather the primary disclosure of the financial event itself.
2026-01-14 Korean
전환가액의조정 (제5회차)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from S-Biomedics regarding the adjustment of the conversion price for its 5th series convertible bonds. It details the calculation methodology, the change in conversion price, and the impact on the number of convertible shares. This type of disclosure is a standard corporate action related to capital structure and financing instruments, which falls under the 'Capital/Financing Update' category.
2026-01-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (Kang Saeil) and special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-01-09 Korean
주주명부폐쇄기간또는기준일설정
Notice of Dividend Amount Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date and shareholder register closure for an upcoming Annual General Meeting (AGM). It does not contain the full meeting materials or proxy statements, but rather serves as a formal regulatory notice of the administrative procedure for the meeting. Given the nature of the announcement as a regulatory disclosure, it fits best under the RNS category.
2025-12-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.